Bavencio Administration Details: Form, Potency, Usage Instructions, and Additional Information
In the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma, the immunotherapy drug Bavencio (avelumab) is a viable option for both adults and certain children.
For adults and adolescents aged 12 years and older with Merkel cell carcinoma, the recommended dosage is 800 mg administered as an intravenous infusion every 2 weeks. In the case of urothelial carcinoma, the dosing is similar for adults whose cancer has progressed after prior treatments, with the same dosing schedule of 800 mg IV every 2 weeks.
For renal cell carcinoma, Bavencio is used in combination with axitinib (another anticancer drug) at the same dose of 800 mg IV every 2 weeks for adults. However, the use of Bavencio in children under 12 is not recommended.
It is crucial to note that the dosing regimens for children under 12 or for pediatric patients are not explicitly stated in the current research, except for the note that Bavencio is not recommended for children and adolescents below 18 years, except for Merkel cell carcinoma patients aged 12 and older.
When it comes to the administration of Bavencio, it is given as an IV infusion by a healthcare professional and is intended to be a long-term treatment. The infusion process takes approximately 60 minutes.
For those under 30 kg weight, specific dosing guidelines may vary, but these were not found in the results for Bavencio. Consulting specific prescribing information or oncology guidelines is advised for detailed dosing adjustments, infusion duration, or management for special populations.
In summary, the dosing for Bavencio in the treatment of Merkel cell carcinoma, urothelial carcinoma, and renal cell carcinoma is as follows:
| Indication | Age Group | Dose | Frequency | |---------------------------|--------------------------|-------------------------------|-------------------| | Merkel cell carcinoma | Adults and ≥12 years old | 800 mg IV | Every 2 weeks | | Urothelial carcinoma | Adults | 800 mg IV | Every 2 weeks | | Renal cell carcinoma | Adults (with axitinib) | 800 mg IV | Every 2 weeks | | Pediatric (<12 years) | Not recommended | N/A | N/A |
Before starting treatment with Bavencio, your doctor will discuss your treatment plan with you. If you miss your Bavencio infusion appointment, it is important to call your doctor's office to reschedule.
Read also:
- Impact of Alcohol Consumption During Pregnancy: Consequences and Further Details
- The cause behind increased urination after alcohol consumption is explained here.
- Toe joint arthritis: Signs, triggers, and further details
- West Nile Virus found in Kentucky for the first time; residents advised to take protective measures
